Replies to post #96361 on Biotech Values

[ghmm]

Thanks I missed that the call was now!

[DewDiligence]

One Telaprevir patient in the ADVANCE study developed Stevens-Johnson Syndrome, but this was not judged to be Telaprevir-related because SJS emerged 11 weeks after the patient completed the regimen of Telaprevir.

There had been rumors for the past year or so that one Telaprevir patient had developed a devastating rash; now we know what the rumors stemmed from.

[DewDiligence]

The overall rash rate was ~50% in the Telaprevir arms and ~30% in the control arm.